文献速递心外重症与机械循环支持

左心室辅助系统与感染相关结局:MOMENTUM 3试验综合分析

Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial.
PubMed 文献 · J Heart Lung Transplant · 2020-03-20

基于MOMENTUM 3随机对照试验的1,020例患者(HM3组515例,HMII组505例),分析持续机械循环支持2年内的感染相关结局。HM3与HMII的重大感染发生率分别为58%和56%(p=0.57),器械选择未改变感染结局;感染事件以非泵组件相关的局部感染最常见(56%),细菌病原体占66%,女性、术前使用IABP、心脏手术史和BMI≥30是感染显著预测因素。

要点

  • HM3与HMII的2年重大感染发生率无显著差异(58% vs 56%,p=0.57)。
  • 感染事件以非泵组件相关的局部感染最常见,占56%。
  • 女性、术前IABP、心脏手术史和BMI≥30是感染显著预测因素。

核心结论

  • 感染是当代持续流式LVAD患者最常见的不良事件,多数感染事件与泵或其外周组件无关。

研究设计与样本

  • MOMENTUM 3试验的试验水平分析,共纳入1,020例植入HM3(n=515)或HMII(n=505)的患者。
  • 评估2年支持期间感染相关结局的临床模式,采用单变量和多变量模型识别重大感染并发症的预测因素。

主要发现

  • 2年累计感染事件数为1,213例次(HM3组634例次,HMII组579例次)。
  • 重大感染发生于58%的HM3患者和56%的HMII患者(p=0.57)。
  • 感染类型分布:非泵组件相关的局部感染681/1,213(56%),驱动线相关感染329/1,213(27%),脓毒症194/1,213(16%),其他事件9/1,213(0.7%)。
  • 细菌病原体涉及806/1,213例次事件(66%)。
  • 感染显著预测因素包括:性别(女性 vs 男性;HR 1.38,p=0.003)、术前使用主动脉内球囊反搏(HR 1.33,p=0.02)、术前心脏手术史(HR 1.28,p=0.01)、体重指数≥30(HR 1.40,p<0.0001)。

临床怎么用

  • 临床应关注LVAD患者感染风险,尤其对女性、术前使用IABP、有心脏手术史及BMI≥30的高危患者加强监测。
  • 多数感染为非泵组件相关的局部感染,提示感染防控需关注整体护理而非仅器械本身。

局限性

  • 本文为试验水平分析,未报告多变量模型的具体校正变量及完整局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a randomized controlled trial (MOMENTUM 3), the HeartMate 3 (HM3) fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) demonstrated superiority over the HeartMate II (HMII) axial-flow LVAD. These findings were driven by hemocompatibility-related outcomes, but infection-related outcomes were not altered by device choice. In this trial-level analysis, we analyzed the clinical patterns of infection-related outcomes over 2 years of support. METHODS: In MOMENTUM 3, 1,020 patients were implanted with either the HM3 (n = 515) or HMII (n = 505) pump. Clinical characteristics and morbidity- and mortality-related outcomes were evaluated to identify predictors associated with major infectious complications, using univariable and multivariable models. RESULTS: The cumulative number of infections at 2 years was 1,213 (634 HM3 and 579 HMII), and major infection occurred in 58% of patients with the HM3 and 56% of patients with the HMII (p = 0.57). Infections of a local nature unrelated to pump components were most common (n = 681/1,213; 56%), followed by driveline-associated infection (n = 329/1,213; 27%), sepsis (n = 194/1,213; 16%), and other events (n = 9/1,213; 0.7%). Bacterial pathogens were implicated in 806 of 1,213 events (66%); significant predictors of infection included sex (women vs men; hazard ratio [HR]: 1.38, p = 0.003), pre-implant use of intra-aortic balloon pump (HR: 1.33, p = 0.02), pre-implant history of cardiac surgery (HR: 1.28, p = 0.01), and body mass index ≥ 30 (HR: 1.40, p < 0.0001). Most deaths in those with infection occurred owing to non-infectious causes. CONCLUSION: Infection is the most common adverse effect in patients implanted with contemporary continuous-flow LVADs, with most such events unrelated to the pump or its peripheral components. Whether chronic mechanical circulatory devices confer an immunomodulatory effect pre-disposing to infection warrants closer scrutiny to understand and ameliorate this morbidity.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Patel CB, Blue L, Cagliostro B, et al. Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial. J Heart Lung Transplant. 2020. PMID: 32276809. doi:10.1016/j.healun.2020.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。